Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PCSA
PCSA logo

PCSA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Processa Pharmaceuticals Inc (PCSA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.120
1 Day change
-1.40%
52 Week Range
19.620
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Processa Pharmaceuticals Inc (PCSA) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators show bearish trends, no significant trading signals are present, and there is a lack of positive news or catalysts. Additionally, no financial performance data or analyst ratings are available to support a buy decision.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating bearish momentum. The RSI is neutral at 39.432, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 1.968, and resistance is at 2.61. The stock is trending downward with a 60% chance of further declines in the next week.

Positive Catalysts

  • NULL identified. No recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

  • Bearish technical indicators, lack of positive news or catalysts, and a projected decline in the short term (-3.02% in the next week).

Financial Performance

No financial data available for the latest quarter.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data available.

Wall Street analysts forecast PCSA stock price to rise
Analyst Rating
0
Wall Street analysts forecast PCSA stock price to rise
Buy
Hold
Sell
0
Current: 2.150
sliders
Low
0
Averages
0
High
0
0
Current: 2.150
sliders
Low
0
Averages
0
High
0
H.C. Wainwright
Raghuram Selvaraju
Buy
downgrade
$2 -> $1
AI Analysis
2025-09-02
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
$2 -> $1
AI Analysis
2025-09-02
downgrade
Buy
Reason
H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on Processa Pharmaceuticals to $1 from $2 and keeps a Buy rating on the shares. The firm cites equity dilution from the strategic investment for the target cut.
H.C. Wainwright
Buy
downgrade
$6 -> $2
2025-06-30
Reason
H.C. Wainwright
Price Target
$6 -> $2
2025-06-30
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Processa Pharmaceuticals to $2 from $6 and keeps a Buy rating on the shares after the company recently announced that it had raised a total of $7M in gross proceeds from an equity financing involving the sale of common shares, pre-funded warrants and warrants to purchase common stock. The equity financing lengthens the runway through key clinical development milestone, but the firm is lowering its price target to account for dilution, the analyst noted.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PCSA
Unlock Now

People Also Watch